1st Oct 2018 15:29
1 October 2018
PDMR SHAREHOLDINGS
Further to the Result of Placing announcement on Thursday 27 September 2018 regarding the placing of 9,467,456 new ordinary shares (the "Placing Shares"), Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company') announces the following PDMR dealings in accordance with Article 19 of the Market Abuse Regulation:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Shaun Chilton | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Director participation in Placing | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
845p per share | 7,101 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
7,101 845p £60,003.45 | |
f) | Date of the transaction | 1 October 2018 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Anne Hyland | |
2 | Reason for the notification | ||
a) | Position/status | Non-Executive Director | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Clinigen Group plc | |
b) | Legal Entity Identifier | 213800OBIKGI2JYYS227 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.1 pence each
GB00B89J2419 | |
b) | Nature of the transaction | Director participation in Placing | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
845p per share | 4,142 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
4,142 845p £34,999.90 | |
f) | Date of the transaction | 1 October 2018 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer Matt Parrish, Head of Investor Relations | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) |
|
| |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Alex Shaw | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L